Cargando…

Vitamin D3 Metabolites Demonstrate Prognostic Value in EGFR-Mutant Lung Adenocarcinoma and Can be Deployed to Oppose Acquired Therapeutic Resistance

EGFR tyrosine kinase inhibitors (EGFR TKIs) are the standard of care treatment for patients with EGFR-mutant lung adenocarcinoma (LUAD). Although initially effective, EGFR TKIs are not curative. Disease inevitably relapses due to acquired drug resistance. We hypothesized that vitamin D metabolites c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shaurova, Tatiana, Dy, Grace K, Battaglia, Sebastiano, Hutson, Alan, Zhang, Letian, Zhang, Yunkai, Lovly, Christine M, Seshadri, Mukund, Goodrich, David W, Johnson, Candace S, Hershberger, Pamela A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140110/ https://www.ncbi.nlm.nih.gov/pubmed/32183160 http://dx.doi.org/10.3390/cancers12030675

Ejemplares similares

Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer
por: Shaurova, Tatiana, et al.
Publicado: (2020)

A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer
por: Shaurova, Tatiana, et al.
Publicado: (2023)

Diet-derived 25-hydroxyvitamin D3 activates vitamin D receptor target gene expression and suppresses EGFR mutant non-small cell lung cancer growth in vitro and in vivo
por: Verone-Boyle, Alissa R., et al.
Publicado: (2015)

Interfering with Autophagy: The Opposing Strategies Deployed by Legionella pneumophila and Coxiella burnetii Effector Proteins
por: Thomas, David R., et al.
Publicado: (2020)

Linking ATP and allosteric sites to achieve superadditive binding with bivalent EGFR kinase inhibitors
por: Heppner, David, et al.
Publicado: (2023)

Preclinical Prevention Trial of Calcitriol: Impact of Stage of Intervention and Duration of Treatment on Oral Carcinogenesis
por: Vincent-Chong, Vui King, et al.
Publicado: (2019)

Opposing Effects of Inhibitors of Aurora-A and EGFR in Autosomal-Dominant Polycystic Kidney Disease
por: Nikonova, Anna S., et al.
Publicado: (2015)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

Estrogen and EGFR Pathways Regulate Notch Signaling in Opposing Directions for Multi-Ciliogenesis in the Fallopian Tube
por: Zhu, Maobi, et al.
Publicado: (2019)

Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
por: Zhang, Chen, et al.
Publicado: (2021)

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review
por: Guo, Yijia, et al.
Publicado: (2020)

YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics
por: Fan, Pang-Dian, et al.
Publicado: (2018)

Structure-Guided Strategies of Targeted Therapies for Patients with EGFR-Mutant Non–Small Cell Lung Cancer
por: Du, Zhenfang, et al.
Publicado: (2023)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
por: Li, Ling, et al.
Publicado: (2020)

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
por: Zhang, Nana, et al.
Publicado: (2017)

The FELIX detector interface for the ATLAS TDAQ upgrades and its deployment in the ITK demonstrator setup
por: Solans, Carlos
Publicado: (2019)

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
por: Tabara, Keisuke, et al.
Publicado: (2012)

Overcoming acquired resistance of EGFR‐mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib, with the natural product honokiol
por: Zang, Hongjing, et al.
Publicado: (2020)

Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma
por: Lee, Po-Hsin, et al.
Publicado: (2022)

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer
por: Van Emburgh, Beth O., et al.
Publicado: (2016)

Inhibition of osteopontin overcomes acquired resistance to afatinib in EGFR-mutant non-small-cell lung cancer
por: Zhang, Hongye, et al.
Publicado: (2020)

Pathogenic Yeasts Deploy Cell Surface Receptors to Acquire Iron in Vertebrate Hosts
por: Kronstad, James W., et al.
Publicado: (2013)

First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
por: Xu, Qinghua, et al.
Publicado: (2019)

EGFR Signal-Network Reconstruction Demonstrates Metabolic Crosstalk in EMT
por: Choudhary, Kumari Sonal, et al.
Publicado: (2016)

Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
por: Roper, Nitin, et al.
Publicado: (2020)

Evolution of MET and NRAS gene amplification as acquired resistance mechanisms in EGFR mutant NSCLC
por: Peters, T. L., et al.
Publicado: (2021)

Astrobiology - an opposing view
por: Shapshak, Paul
Publicado: (2018)

Opposing Child Labor
Publicado: (1914)

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
por: Du, Xiaojing, et al.
Publicado: (2021)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
por: Wang, Wenxian, et al.
Publicado: (2019)

Rab25-Mediated EGFR Recycling Causes Tumor Acquired Radioresistance
por: Zhang, Lu, et al.
Publicado: (2020)

Editorial to the head and neck cancer—series
por: Seshadri, Mukund
Publicado: (2021)

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
por: Miyoshi, Seigo, et al.
Publicado: (2015)

Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
por: Santoni-Rugiu, Eric, et al.
Publicado: (2019)

Targeting BRAF Activation as Acquired Resistance Mechanism to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small-Cell Lung Cancer
por: Aboubakar Nana, Frank, et al.
Publicado: (2021)

EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
por: Uribe, Mary Luz, et al.
Publicado: (2021)

Response to Pralsetinib Observed in Meningeal-Metastatic EGFR-Mutant NSCLC With Acquired RET Fusion: A Brief Report
por: Zhao, Zichen, et al.
Publicado: (2022)

Contribution of KRAS mutations and c.2369C > T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA
por: Del Re, Marzia, et al.
Publicado: (2016)

NF-κB drives acquired resistance to a novel mutant-selective EGFR inhibitor
por: Galvani, Elena, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_5oio3np8cpaiaeng4f9ggvtssv